Expression and Role of the Adrenomedullin System in Melanoma | Chapter 3 | Medical Research and Its Applications Vol. 2

 

The present study performed a combination of In vitro and In vivo tests, examining the role of the AM system on the growth of melanoma cell lines and xenografts, respectively. Even though targeted medicines and immunotherapies have made tremendous progress, metastatic melanoma is an aggressive disease that can provide a serious therapeutic challenge. This underscores the necessity for the identification of new therapeutic targets. Adrenomedullin (AM) is a multifunctional peptide that is expressed significantly in many tumor types. By binding to calcitonin receptor-like receptor/receptor activity-modifying protein 2 or 3 (CLR/RAMP2; CLR/RAMP3), AM affects angiogenesis and tumor progression. In vitro and in vivo studies were performed to determine the functional role of AM in melanoma growth and tumor-associated angiogenesis and lymphangiogenesis. AM and AM receptors were immunohistochemically localized in the tumoral compartment of melanoma tissue, suggesting that the AM system plays a role in melanoma growth. We used A375, SK-MEL-28, and MeWo cells, for which we demonstrated an expression of AM and its receptors; hypoxia induces the expression of AM in melanoma cells. The proliferation of A375 and SK-MEL-28 cells is decreased by anti-AM antibody (αAM) and anti-AMR antibodies (αAMR), supporting the fact that AM may function as a potent autocrine/paracrine growth factor for melanoma cells. Furthermore, migration and invasion of melanoma cells increased after treatment with AM and decreased after treatment with αAMR, thus indicating that melanoma cells are regulated by AM. Reduced numbers of vessel structures showed that systemic administration of αAMR decreased the neovascularization of in vivo Matrigel plugs containing melanoma cells. This suggests that AM is one of the factors derived from melanoma cells that is responsible for endothelial cell-like and pericyte recruitment in the construction of neovascularization. Tumor regression was achieved in vivo by αAMR treatment, which inhibited angiogenesis and lymphangiogenesis and reduced proliferation in MeWo xenografts. Upon histological evaluation, tumors treated with aAMR exhibited indications of disrupted tumor vascularity, including a notable reduction in lymphatic endothelial cells and a depletion of vascular endothelial cells. Finally, the representation of AM by melanoma cells promotes tumor growth and neovascularization by supplying/amplifying signals for neoangiogenesis and lymphangiogenesis.

 

Author(s)details:-

 

Zohra Benyahia
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.

 

Caroline Gaudy-Marqueste
Aix Marseille University, APHM, CHU Timone, Service de Dermatologie et de Cancérologie Cutanée, 13005 Marseille, France.

 

Caroline Berenguer-Daizé
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.

 

Norhimane Chabane
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.

 

Nadège Dussault
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.

 

Mylène Cayol
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.

 

Christine Vellutini
Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France

 

Amina Djemli
Aix Marseille University, APHM, CHU Nord, Service D’anatomopathologie, 13015 Marseille, France.

 

Isabelle Nanni
Aix Marseille University, CNRS, ICR, Institut de Chimie Radicalaire, 13013 Marseille, France.

 

Nathalie Beaufils
Aix Marseille University, CNRS, ICR, Institut de Chimie Radicalaire, 13013 Marseille, France.

 

Kamel Mabrouk
Aix Marseille University, APHM, CHU Nord, Service D’Onco-Biologie, 13015 Marseille, France.

 

Jean-Jacques Grob
Aix Marseille University, APHM, CHU Timone, Service de Dermatologie et de Cancérologie Cutanée, 13005 Marseille, France.

 

Please See the book here :- https://doi.org/10.9734/bpi/mria/v2/8351E

Dynamic Fibroblasts Turn a Tumoroid to a Tumor | Chapter 3 | Advanced Concepts in Medicine and Medical Research Vol. 11

Tumoroids are the tumor-cell derived Cancer-like organoids generated in the testing room with or without utilizing of 3D scaffolds. Whereas, a swelling tissue is a result of in vivo multi-cellular complex institution that supports cancer containers and other tumor-joined cells (TACs), for instance, fibroblasts & endothelial cells, for the participation and the arrangement to establish the appropriate physio-dynamic environment for a Cancer growth. Because creating such an atmosphere in lab through artificial culture is still a challenge, the implantation of tumoroids into the animal tissues to produce tumors becomes coarse practice. Predominantly presence of the fibroblasts in the plant structure sections of a dependable tumor indicates that swelling cannot establish the liberal growth without fibroblasts. Following information that is designed to mislead or persuade, tumor containers in a tumoroid signal the local tissue microenvironment to recruit fibroblasts and other TACs. Energetically participation and renewal of fibroblasts to cancer-associated fibroblasts (CAFs) eventually lead to the switching of a tumoroid to a tumor. This book chapter thus discusses about fibroblasts and CAFs, and their duty to establish the tumor from an inserted tumoroid into the animal tissue.

Author(s) Details:

Girdhari Rijal,
Department of Medical Laboratory Sciences, Public Health & Nutrition Science, College of Health Sciences, Tarleton State University, Member of Texas A & M University System, Fort Worth, Texas 76104, USA.

Please see the link here: https://stm.bookpi.org/ACMMR-V11/article/view/12886